Medication Guide App

Label Changes for:

Jentadueto (linagliptin and metformin hydrochloride) tablets, 2.5 mg/500 mg, 2.5 mg/850 mg, and 2.5 mg/1000 mg

September 2013

Changes have been made to the WARNINGS and PRECAUTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

 

September 2013

5 WARNINGS AND PRECAUTIONS

5.2 Pancreatitis
  • There have been postmarketing reports of acute pancreatitis, including fatal pancreatitis, in patients taking linagliptin. Take careful notice of potential signs and symptoms of pancreatitis. If pancreatitis is suspected, of pancreatitis are at increased risk for the development of pancreatitis while using JENTADUETO.
5.5 Use with Medications Known to Cause Hypoglycemia

Linagliptin

  • Insulin secretagogues and insulin are known to cause hypoglycemia. The use of linagliptin in combination with an insulin secretagogue (e.g., sulfonylurea) was associated with a higher rate of hypoglycemia compared with placebo in a clinical trial [see Adverse Reactions (6.1)]. The use of linagliptin in combination with insulin in subjects with severe renal
  • Therefore, a lower dose of the insulin secretagogue or insulin may be required to reduce the risk of hypoglycemia when used in combination with JENTADUETO [see Dosage and Administration (2.2)].

Note: labeling changes align the Jentadueto label with the updated information in the current Tradjenta label

 

 

June 2013

WARNINGS AND PRECAUTIONS

Pancreatitis
  • There have been postmarketing reports of acute pancreatitis, including fatal pancreatitis, in patients taking linagliptin. Take careful notice of potential signs and symptoms of pancreatitis. If pancreatitis is suspected, promptly discontinue Jentadueto and initiate appropriate management. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using Jentadueto.
 
Hide
(web5)